Open AccessA Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
Author(s) -
Qingqing Li,
Tong Su,
Xu Zhang,
Yanfeng Pan,
Shengli Ma,
Lu Zhang,
Xianqiang Zhang,
Xiaojuan Gao
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s379911
Subject(s) - medicine , clinical endpoint , hepatocellular carcinoma , adverse effect , progressive disease , regimen , oncology , combination therapy , confidence interval , response evaluation criteria in solid tumors , gastroenterology , progression free survival , disease , overall survival , randomized controlled trial
To observe the efficacy and safety of anlotinib as a first-line treatment for patients with advanced hepatocellular carcinoma (aHCC) in a real-word environment, explore the optimal treatment regimen for patients with aHCC using anlotinib as a first-line treatment.